Active ingredient: Sertraline
Note about medicines names
Most medicines have two names: the active ingredient and the brand name. The active ingredient is the chemical in the medicine that makes it work. The brand name is the name given to the medicine by its manufacturer. There may be several brands that contain the same active ingredient. This website uses active ingredient names (e.g. amoxycillin), with brand names in brackets and with a capital letter (e.g. Amoxil). We also discuss medicines in groups or ‘classes’ when their effects or actions are very similar.
What is sertraline?
Sertraline is a type of antidepressant called a selective serotonin reuptake inhibitor (SSRI). It is used to treat depression and some other illnesses.
Find out more about
- What sertraline does and how effective it is
- Who sertraline is for and who should be cautious
- Side effects of sertraline
- Interactions with sertraline
- Brands of sertraline
If you are starting sertraline, see 10 things you should know about antidepressants.
For more information
- Starting, switching and stopping antidepressants
- Managing side effects of antidepressants
- Psychological therapies
The consumer medicine information (CMI) for your brand of sertraline is available from our website or a pharmacist. The CMI includes:
- how to take this medicine
- what to do if you forget to take it
- if you take too much (overdose)
- things you must and must not do while taking this medicine
- signs of severe reactions and what to do.
- Rossi S, ed. eAMH [online]. Adelaide: Australian Medicines Handbook, July 2012.
- Psychotropic Expert Group. Therapeutic Guidelines: Psychotropic, Version 6. In: eTG complete [CD-ROM]. Melbourne: Therapeutic Guidelines Limited; 2008.
- Williams JW Jr, Mulrow CD, Chiquette E, et al. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med 2000;132:743–56. [PubMed]
- Pfizer Australia Pty Ltd. Zoloft consumer medicine information. December 2011. (Accessed 22 March 2012).
- National Collaborating Centre for Mental Health. Depression: the NICE guideline on the treatment and management of depression in adults (updated edition). London: National Institute for Health and Clinical Excellence, 2010. www.nice.org.uk/nicemedia/live/12329/45896/45896.pdf (accessed 9 February 2012).
- Gartlehner G, Hansen RA, Morgan LC, et al. Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis. Ann Intern Med 2011;155:772–85. [PubMed]